Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been given a consensus rating of “Hold” by the nine analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $28.75.

Several analysts have recently issued reports on LXRX shares. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Wedbush reiterated an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday. BidaskClub downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th.

Shares of Lexicon Pharmaceuticals (LXRX) opened at 14.51 on Friday. Lexicon Pharmaceuticals has a 12 month low of $13.41 and a 12 month high of $19.62. The company’s 50 day moving average price is $16.24 and its 200-day moving average price is $15.41. The firm’s market capitalization is $1.53 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The business had revenue of $12 million for the quarter, compared to the consensus estimate of $18.34 million. During the same period in the prior year, the business earned ($0.37) earnings per share. The business’s revenue was down 40.3% on a year-over-year basis. On average, equities analysts predict that Lexicon Pharmaceuticals will post ($1.45) earnings per share for the current fiscal year.

WARNING: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2801818/lexicon-pharmaceuticals-inc-nasdaqlxrx-receives-average-recommendation-of-hold-from-brokerages.html.

Institutional investors have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S increased its position in Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 280 shares during the period. 361 Capital LLC acquired a new position in Lexicon Pharmaceuticals during the first quarter valued at $186,000. First Mercantile Trust Co. increased its position in Lexicon Pharmaceuticals by 11.2% in the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the period. Cim Investment Mangement Inc. acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at $262,000. Finally, Pacad Investment Ltd. acquired a new position in Lexicon Pharmaceuticals during the second quarter valued at $265,000.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.